Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
24 April 2025
| Name: | INCANNEX HEALTHCARE LIMITED (IHL) | |||||||||
| ISIN: | AU000000IHL8 | |||||||||
| Date of Listing: | 23 May 2007 | |||||||||
| Date of Delisting: | 29 November 2023 | |||||||||
| Former Names: |
|
Stock Exchange Status:
This entity was delisted from the Australian Securities Exchange on 29 November 2023.Legal Status:
ACN: 096 635 246ABN: 93 096 635 246
Registration Date: 27 April 2001
Capital Gains Tax (CGT) Status:
To our knowledge this entity was the subject of a takeover or merger such that your securities were acquired for consideration in the form of cash or scrip. You will need to seek independent tax advice in relation to Capital Gains Tax or other tax matters but any other enquiries relating to your shareholding in the company should be followed up via our online form here: https://www.delisted.com.au/TraceLostSharesLostMoney/index/.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
| Company | FROM | TO |
|---|---|---|
| INCANNEX HEALTHCARE LIMITED | 05/07/2020 | |
| IMPRESSION HEALTHCARE LIMITED | 31/10/2016 | 06/07/2020 |
| MOUNT MAGNET SOUTH LIMITED | 03/12/2015 | 31/10/2016 |
| MOUNT MAGNET SOUTH NL | 03/12/2015 |
REGISTRY:
Computershare Investor Services
P.O. Box 43078 Providence, RI 02940-3078 United States of America
RegistryWebsite
delisted at entity's request under Listing Rule 17.11 | 29/11/2023 |
we understand under a scheme of arrangement Incannex Healthcare Inc. acquired all of the issued securities in IHL (at 1 new share or option for every 100 existing shares or options - except small parcel holders will eventually receive cash) effectively re-domiciling to the US and with shares listed on NASDAQ - Computershare US is the registry | 29/11/2023 |
The securities of Incannex Healthcare Limited will be suspended from quotation at the close of trading on Friday, 17 November 2023 under Listing Rule 17.2, following lodgement of the Federal Court of Australia orders with ASIC approving the scheme of arrangement by which Incannex Healthcare Inc. will acquire all of the issued securities in IHL. | 17/11/2023 |
The suspension of trading in the securities of Incannex Healthcare Limited will be lifted immediately following the release by IHL of an announcement regarding a material update regarding IHL's psychedelic program. | 15/03/2023 |
Interim analysis of study data to date indicates that there is a greater than 85% chance (>85%, alpha error probability 0.05) of the study showing a statistically significant benefit for the psilocybin treatment arm versus the placebo treatment arm at the conclusion of the study period. An independent Data Safety Monitoring Board (DSMB) has reviewed data from Incannex's ongoing Phase 2 "PsiGAD" clinical trial and recommends no changes to study design. The trial team and DSMB have identified no safety concerns to date. | 15/03/2023 |
The securities of Incannex Healthcare Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of IHL, pending the release of an announcement regarding a material update regarding IHL's psychedelic program. | 14/03/2023 |
name changed from Impression Healthcare Limited | 06/07/2020 |
delisted at entity's request under Listing Rule 17.11 | 29/11/2023 |
we understand under a scheme of arrangement Incannex Healthcare Inc. acquired all of the issued securities in IHL (at 1 new share or option for every 100 existing shares or options - except small parcel holders will eventually receive cash) effectively re-domiciling to the US and with shares listed on NASDAQ - Computershare US is the registry | 29/11/2023 |
The securities of Incannex Healthcare Limited will be suspended from quotation at the close of trading on Friday, 17 November 2023 under Listing Rule 17.2, following lodgement of the Federal Court of Australia orders with ASIC approving the scheme of arrangement by which Incannex Healthcare Inc. will acquire all of the issued securities in IHL. | 17/11/2023 |
The suspension of trading in the securities of Incannex Healthcare Limited will be lifted immediately following the release by IHL of an announcement regarding a material update regarding IHL's psychedelic program. | 15/03/2023 |
Interim analysis of study data to date indicates that there is a greater than 85% chance (>85%, alpha error probability 0.05) of the study showing a statistically significant benefit for the psilocybin treatment arm versus the placebo treatment arm at the conclusion of the study period. An independent Data Safety Monitoring Board (DSMB) has reviewed data from Incannex's ongoing Phase 2 "PsiGAD" clinical trial and recommends no changes to study design. The trial team and DSMB have identified no safety concerns to date. | 15/03/2023 |
The securities of Incannex Healthcare Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of IHL, pending the release of an announcement regarding a material update regarding IHL's psychedelic program. | 14/03/2023 |
name changed from Impression Healthcare Limited | 06/07/2020 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NATURE | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|---|
| 31/10/2023 | Peter Widdows | 510,954 | $0.066 | $33,842 | |
| 23/03/2018 | Alistair Blake | 35,000 | $0.033 | $1,140 | |
| 04/12/2017 | Kelvin Smith | 90,000 | $0.021 | $1,879 | |
| 02/06/2017 | Alistair Blake | 25,691 | $0.041 | $1,048 | |
| 24/05/2017 | Alistair Blake | 34,466 | $0.056 | $1,916 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Troy Valentine | Non Exec Chairman | 13/12/2017 |
| Joel Latham | Managing Director, CEO | 19/07/2018 |
| Lekhram Changoer | CTO | 28/06/2022 |
| Peter Widdows | Non Exec Director | 01/03/2018 |
| George Anastassov | Director | 28/06/2022 |
| Robert B. Clark | Director | 17/08/2022 |
| Madhukar Bhalla | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Sud Agarwal | Non Exec Director | 25/07/2019 | 28/06/2022 |
| Alistair Blake | Director | 20/10/2016 | 25/07/2019 |
| Matthew Weston | Managing Director, CEO | 01/02/2016 | 19/07/2018 |
| Adam Wellisch | Independent Director | 03/04/2017 | 08/05/2018 |
| Kelvin Smith | Director | 20/10/2016 | 12/12/2017 |
| John Worsfold | Director | 20/10/2016 | 12/12/2017 |
| Alec Pismiris | Non Exec Chairman | 02/08/2013 | 03/04/2017 |
| Michael Fennell | Director | 22/12/2014 | 20/10/2016 |
| David Leavy | Director | 22/12/2014 | 20/10/2016 |
| Mark Pitt | Non Exec Director | 26/10/2010 | 22/12/2014 |
| Patrick Flint | Non Exec Director | 15/04/2011 | 22/12/2014 |
| Colin Chenu | Non Exec Director | 14/09/2010 | 25/11/2013 |
| Phillip Shreeve | CFO | 01/06/2011 | 01/10/2013 |
| Reginald Gillard | Non Exec Chairman | 15/04/2011 | 02/08/2013 |
| Matthew Shackleton | Managing Director | 18/04/2008 | 10/02/2012 |
| Frederick McMurray | Director | 26/07/2007 | 11/11/2010 |
| David G. Sanders | Alternate Director | 24/09/2010 | 02/10/2010 |
| Geoffrey Motteram | Director | 31/05/2006 | 16/09/2010 |
| Geoffrey Newman | Non Exec Chairman | 31/05/2006 | 11/09/2010 |
| John Stockley | Non Exec Director | 31/05/2006 | 19/08/2009 |
| Phillip Botsis | Non Exec Chairman | 31/05/2006 | 18/09/2008 |
| Andrew Paterson | Managing Director | 14/11/2006 | 06/04/2008 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2025 Investogain Pty Limited. All rights reserved.
